natgillin/translations-raw huggingface dataset:
Irbesartan/Hydrochlorthiazid Teva 300 mg/25 mg filmovertrukne tabletter Hver filmovertrukket tablet indeholder 300 mg irbesartan og 25 mg hydrochlorthiazid. 
Irbesartan/Hydrochlorothiazide Teva 300 mg/25 mg film-coated tablets Each film-coated tablet contains 300 mg of irbesartan and 25 mg of hydrochlorothiazide.
Hvis du får et eller flere af disse symptomer eller får åndenød, skal du holde op med at tage 
If you get any of these symptoms or get short of breath, stop taking Irbesartan/Hydrochlorothiazide Teva and contact your doctor immediately.
Begrænsede kliniske data (7 patienter ud af 22) tyder på, at patienter, som ikke er regulerede med 300 mg/12,5 mg-kombinationen, kan respondere ved dosisøgning til 300/25 mg. Der er hos disse patienter observeret en øgning i blodtryksreduktionen for såvel systolisk blodtryk (SBP) som diastolisk blodtryk (DBP) (henholdsvis 13,3 mm Hg og 8,3 mm Hg). 
Limited clinical data (7 out of 22 patients) suggest that patients not controlled with the 300 mg/12.5 mg combination may respond when uptitrated to 300 mg/25 mg.
Thiaziddiuretika øger urinudskillelse og sænker derved blodtrykket. 
Hydrochlorothiazide is one of a group of medicines (called thiazide diuretics) that causes increased urine output and so causes a lowering of blood pressure.
Irbesartan/Hydrochlorthiazid Teva 150 mg/12,5 mg filmovertrukne tabletter Hver filmovertrukket tablet indeholder 150 mg irbesartan og 12,5 mg hydrochlorthiazid. 
Irbesartan/Hydrochlorothiazide Teva 150 mg/12.5 mg film-coated tablets Each film-coated tablet contains 150 mg of irbesartan and 12.5 mg of hydrochlorothiazide.
Indlægsseddel: Information til brugeren Irbesartan/Hydrochlorthiazid Teva 150 mg/12,5 mg filmovertrukne tabletter irbesartan / hydrochlorthiazid 
Package leaflet: information for the patient Irbesartan/Hydrochlorothiazide Teva 150 mg/12.5 mg film-coated tablets irbesartan / hydrochlorothiazide
Irbesartan/Hydrochlorthiazid Teva 300 mg/12,5 mg filmovertrukne tabletter irbesartan/hydrochlorthiazid 
Irbesartan/Hydrochlorothiazide Teva 300 mg/12.5 mg film-coated tablets irbesartan/hydrochlorothiazide
Irbesartan/Hydrochlorthiazid Teva 150 mg/12,5 mg filmovertrukne tabletter irbesartan/hydrochlorthiazid 
Irbesartan/Hydrochlorothiazide Teva 150 mg/12.5 mg film-coated tablets irbesartan/hydrochlorothiazide
Det skal du vide, før du begynder at tage Irbesartan/Hydrochlorthiazid Teva Sådan skal du tage Irbesartan/Hydrochlorthiazid Teva Bivirkninger 
What Irbesartan/Hydrochlorothiazide Teva is and what it is used for What you need to know before you take Irbesartan/Hydrochlorothiazide Teva How to take Irbesartan/Hydrochlorothiazide Teva Possible side effects
Der er hverken observeret rebound-hypertension for irbesartan eller hydrochlorthiazid. 
Although not specifically studied with irbesartan/hydrochlorothiazide, rebound hypertension has not been seen with either irbesartan or hydrochlorothiazide.
Indlægsseddel: Information til brugeren Irbesartan/Hydrochlorthiazid Teva 300 mg/12,5 mg filmovertrukne tabletter irbesartan / hydrochlorthiazid 
Package leaflet: information for the patient Irbesartan/Hydrochlorothiazide Teva 300 mg/12.5 mg film-coated tablets irbesartan / hydrochlorothiazide
Forholdet mellem den laveste og den maksimale effekt af irbesartan/hydrochlorthiazid 150 mg/12,5 mg var 100 %, når blodtrykket blev monitoreret ambulant. 
When measured by ambulatory blood pressure monitoring, the trough to peak effects of irbesartan/hydrochlorothiazide 150 mg/12.5 mg were 100 %.
Irbesartan/Hydrochlorthiazid Teva skal tages gennem munden. 
Irbesartan/Hydrochlorothiazide Teva is for oral use.
Irbesartan/Hydrochlorthiazid Teva 300 mg/25 mg filmovertrukne tabletter Pink til mørk pink filmovertrukne kapselformede tabletter. 
Irbesartan/Hydrochlorothiazide Teva 300 mg/25 mg film-coated tablets Pink to dark pink, film-coated capsule shaped tablet.
Irbesartan/Hydrochlorthiazid Teva 300 mg/12,5 mg filmovertrukne tabletter Hver filmovertrukket tablet indeholder 300 mg irbesartan og 12,5 mg hydrochlorthiazid. 
Irbesartan/Hydrochlorothiazide Teva 300 mg/12.5 mg film-coated tablets Each film-coated tablet contains 300 mg of irbesartan and 12.5 mg of hydrochlorothiazide.
Sort jernoxid 
Iron Oxide Black
Irbesartan/Hydrochlorthiazid Teva 300 mg/25 mg filmovertrukne tabletter er pink til mørke pink, filmovertrukne kapselformede tabletter. 
Irbesartan/Hydrochlorothiazide Teva 300 mg/25 mg film-coated tablets are pink to dark pink, film coated capsule shaped tablet.
Irbesartans farmakokinetiske parametre ændres ikke væsentligt hos patienter med nedsat nyrefunktion eller i hæmodialyse. 
In patients with renal impairment or those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan are not significantly altered.
Dosisjustering er ikke nødvendig til patienter med nedsat nyrefunktion, hvis den renale kreatininclearance er > 30 ml/min (se pkt. 
No dosage adjustment is necessary in patients with renal impairment whose renal creatinine clearance is ≥ 30 ml/min (see sections 4.3 and 4.4).
Benigne, maligne og uspecificerede tumorer (inkl. 
Adverse reactions reported with the use of hydrochorothiazide alone Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hypotension og takykardi forventes at være de mest sandsynlige symptomer på irbesartanoverdosering. 
The most likely manifestations of irbesartan overdose are expected to be hypotension and tachycardia; bradycardia might also occur.
Øget serumcarbamid, kreatinin og kreatinkinase 
Increases in blood urea nitrogen (BUN), creatinine and creatine kinase Decreases in serum potassium and sodium
Svækkelse, muskelspasmer bindevæv Vaskulære sygdomme 
Musculoskeletal and connective tissue disorders:
Systemorganklasse 
Method of Administration
Amning 
Flushing
Om nødvendigt kan Irbesartan/Hydrochlorthiazid Teva kombineres med andre antihypertensiva (se pkt. 
When necessary, Irbesartan/HydrochlorothiazideTeva may be administered with another antihypertensive medicinal product (see sections 4.3, 4.4, 4.5 and 5.1).
Irbesartan/Hydrochlorthiazid Teva 150 mg/12,5 mg filmovertrukne tabletter Lys pink til pink, filmovertrukne kapselformede tabletter. 
Irbesartan/Hydrochlorothiazide Teva 150 mg/12.5 mg film-coated tablets Light pink to pink, film-coated capsule shaped tablet.
6.1, eller over for andre sulfonamidderivater (hydrochlorthiazid er et sulfonamidderivat) 
Hypersensitivity to the active substances or to any of the excipients listed in section 6.1, or to other sulfonamide-derived substances (hydrochlorothiazide is a sulfonamide-derived substance) Second and third trimester of pregnancy (see sections 4.4 and 4.6) Severe renal impairment (creatinine clearance < 30 ml/min) Refractory hypokalaemia, hypercalcaemia
Irbesartan/Hydrochlorthiazid Teva 300 mg/12,5 mg filmovertrukne tabletter Lys pink til pink, filmovertrukne kapselformede tabletter. 
Irbesartan/Hydrochlorothiazide Teva 300 mg/12.5 mg film-coated tablets Light pink to pink, film-coated capsule shaped tablet.
Irbesartan/Hydrochlorthiazid Teva 300 mg/12,5 mg filmovertrukne tabletter er lyse pink til pink, filmovertrukne kapselformede tabletter. 
Irbesartan/Hydrochlorothiazide Teva 300 mg/12.5 mg film-coated tablets are light pink to pink, film coated capsule shaped tablets.
Irbesartan/Hydrochlorthiazid Teva 150 mg/12,5 mg filmovertrukne tabletter er lyse pink til pink, filmovertrukne kapselformede tabletter. 
Irbesartan/Hydrochlorothiazide Teva 150 mg/12.5 mg film-coated tablets are light pink to pink, film coated capsule shaped tablets.
Omvendt kan der opstå hyperkaliæmi på grund af irbesartankomponenten i Irbesartan/Hydrochlorthiazid Teva. 
Conversely, due to the irbesartan component of Irbesartan/Hydrochlorothiazide Teva hyperkalaemia might occur, especially in the presence of renal impairment and/or heart failure, and diabetes mellitus.
Oversigt over indlægssedlen: 
Psychiatric disorders:
Gul jernoxid 
Digitalis glycosides
Irbesartan forebygger at angiotensin-II binder sig til disse receptorer. 
Irbesartan prevents the binding of angiotensin-II to these receptors, causing the blood vessels to relax and the blood pressure to lower.
• Aktive stoffer: Irbesartan og hydrochlorthiazid Hver Irbesartan/Hydrochlorthiazid Teva 300 mg/25 mg filmovertrukket tablet indeholder 300 mg irbesartan og 25 mg hydrochlorthiazid. 
Each Irbesartan/Hydrochlorothiazide Teva 300 mg/25 mg film-coated tablet contains 300 mg irbesartan and 25 mg hydrochlorothiazide.
• Samtidig brug af Irbesartan/Hydrochlorthiazid Teva og lægemidler indeholdende aliskiren er kontraindiceret hos patienter med diabetes mellitus eller nedsat nyrefunktion (GFR 
Severe hepatic impairment, biliary cirrhosis and cholestasis The concomitant use of Irbesartan/Hydrochlorothiazide Teva with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
• hvis du oplever øget følsomhed af huden for sol med solskoldningssymptomer (såsom rødme, kløe, hævelse, blæredannelse), som forekommer hurtigere end normalt 
if you experience an increased sensitivity of the skin to the sun with symptoms of sunburn (such as redness, itching, swelling, blistering) occurring more quickly than normal if you are going to have an operation (surgery) or be given anaesthetics if you have changes in your vision or pain in one or both of your eyes while taking Irbesartan/Hydrochlorothiazide Teva.
• Aktive stoffer: Irbesartan og hydrochlorthiazid Hver Irbesartan/Hydrochlorthiazid Teva 300 mg/12,5 mg filmovertrukket tablet indeholder 300 mg irbesartan og 12,5 mg hydrochlorthiazid. 
Each Irbesartan/Hydrochlorothiazide Teva 300 mg/12.5 mg film-coated tablet contains 300 mg irbesartan and 12.5 mg hydrochlorothiazide.
• Aktive stoffer: Irbesartan og hydrochlorthiazid Hver Irbesartan/Hydrochlorthiazid Teva 150 mg/12,5 mg filmovertrukket tablet indeholder 150 mg irbesartan og 12,5 mg hydrochlorthiazid. 
Each Irbesartan/Hydrochlorothiazide Teva 150 mg/12.5 mg film-coated tablet contains 150 mg irbesartan and 12.5 mg hydrochlorothiazide.
Hvis du har taget for mange Irbesartan/Hydrochlorthiazid Teva tabletter 
If you take more Irbesartan/Hydrochlorothiazide Teva than you should
Betingelser for markedsføringstilladelse 
Marketing Authorisation Holder
- Find en bekvem og stabil position. 
- Put yourself in a comfortable and stable position.
- Hvis du har diabetes. 
- if you have diabetes.
Efter første åbning: 4 uger. 
After first opening: 4 weeks.
Behandlingseffekten blev evalueret i op til 29 dage. 
Treatment effect was evaluated up to 29 days.
Brug hos voksne, inklusive ældre patienter 
Use in adults, including the elderly
In vitro var 99,8 % bundet til proteiner i humant plasma. 
In vitro, the 99.8% were bound to proteins in human plasma.
Pakken indeholder 1 flaske. 
Pack of 1 bottle.
Der er ikke udført interaktionsundersøgelser. 
No interaction studies have been performed.
Dato for første markedsføringstilladelse:18.05.2011 Dato for seneste fornyelse:11.01.2016 
Date of first authorisation: 18.05.2011 Date of latest renewal: 11.01.2016
- Vask hænderne inden du bruger øjendråberne. 
- Wash your hands before using the eye drops.
Skyl øjet med varmt vand. 
Rinse out your eye with warm water.
Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information om sikkerheden af dette lægemiddel. 
By reporting side effects you can help provide more information on the safety of this medicine.
Brug ikke Yellox længere end 2 uger. 
Do not use Yellox longer than 2weeks.
Brug en enkelt dosis, så snart du kommer i tanke om det. 
Use a single dose as soon as you remember.
- Hvis du har fået gentagne øjenoperationer inden for et kort tidsrum. 
- if you had repeated eye surgery within a short period of time.
- Hvis du har rheumatoid arthritis (leddegigt). 
- if you have rheumatoid arthritis.
*Alvorlige rapporter fra erfaring efter markedsføring med flere end 20 millioner patienter ** Observeret ved dosering fire gange daglig 
*Serious reports from post-marketing experience of more than 20 million patients ** Observed with four times daily dose
Behandlingen bør ikke overstige 2 uger, da der ikke foreligger sikkerhedsdata for behandling ud over dette tidsrum. 
The treatment should not exceed 2 weeks as safety data beyond this is not available.
Disse hændelser kan true synet. 
These events may be sight threatening.
Fortsæt med den næste sædvanlige planlagte dosis. 
Continue with the next regularly scheduled dose.
Cyclooxygenase 1 (COX-1) hæmmes kun i ringe omfang. 
Cyclooxygenase 1 (COX-1) is only inhibited to a small extent.
Dit syn kan blive sløret i et kort tidsrum efter brug af disse øjendråber. 
Your vision may be blurred for a short time after using this eye drops.
Klar gul opløsning. 
Clear yellow solution.
På grundlag af tilgængelige kliniske data fik i alt 3,4 % af patienterne én eller flere bivirkninger. 
Based on clinical data available, a total of 3.4% of patients experienced one or more adverse reactions.
Kontakt med bløde kontaktlinser skal undgås. 
Contact with soft contact lenses must be avoided.
Anvend ikke flere dråber, før det er tid for den næste sædvanlige dosis. 
Do not put in any more drops until it is time for your next regular dose.
Yellox bør ikke bruges i de sidste tre måneder af graviditeten. 
Yellox should not be used during the last three months of pregnancy.
Det virker ved at blokere visse stoffer, der er involveret i udviklingen af betændelsen. 
It works by blocking certain substances involved in causing inflammation.
Behandling af individer, som tidligere har udvist overfølsomhed over for disse lægemidler skal derfor undgås (se pkt. 
Therefore, treating individuals who have previously exhibited sensitivities to these medicinal products has to be avoided (see section 4.3).
Der er praktisk taget ingen risiko for bivirkninger som følge af utilsigtet oral indtagelse. 
There is practically no risk of adverse effects due to accidental oral ingestion.
Topikal NSAID skal bruges med forsigtighed hos disse patienter. 
Topical NSAIDs should be used with caution in these patients.
- Drej flaskehætten og åbn den. - Vend flasken nedad og hold den mellem tommelfingeren og fingrene. 
- Twist off the bottle cap. - Hold the bottle, pointing down, between your thumb and fingers.
- Træk ned i det nederste øjenlåg med en ren finger. 
- Pull down your lower eyelid with a clean finger.
Brug af Yellox anbefales generelt ikke under graviditet, medmindre fordelen opvejer den potentielle risiko. 
The use of Yellox is in general not recommended during pregnancy unless the benefit outweighs the potential risk.
Det er ukendt, om bromfenac eller dets metabolitter udskilles i human mælk. 
It is unknown whether bromfenac or its metabolites are excreted in human milk.
Kasser flasken 4 uger efter første åbning for at forebygge infektion, også selvom opløsningen ikke er opbrugt. 
Discard the bottle 4 weeks after first opening to prevent infection even if there is solution remaining.
Du må ikke holde op med at bruge Yellox uden at tale med din læge. 
Do not stop using Yellox without speaking to your doctor.
Du må ikke bruge en dobbeltdosis som erstatning for den glemte dosis. 
Do not use a double dose to make up for a forgotten dose.
Utilsigtet administration af mere end én dråbe bør ikke resultere i øget topikal eksponering, da det overskydende volumen vil løbe ud af øjet som følge af begrænset kapacitet i konjunktivalsækken. 
Accidental administration of more than one drop should not result in increased topical exposure as excessive volume would rinse out of the eye due to limited conjunctival sac capacity.
Yellox bør ikke anvendes til børn og unge. 
Yellox should not be used in children and adolescents.
Bromfenac viser høj plasmaproteinbinding. 
Bromfenac shows high binding to plasma proteins.
Skriv datoen for åbning af kartonetiketten i det dertil beregnede område. 
Write the date of opening on the carton label in the space provided.
Da Yellox indeholder benzalkoniumchlorid, er nøje overvågning påkrævet ved hyppig eller længerevarig brug. 
Since Yellox contains benzalkonium chloride, close monitoring is required with frequent or prolonged use.
pH: 8,1-8,5; osmolalitet: 270-330 mOsmol/kg 
pH: 8.1-8.5; osmolality: 270-330 mOsmol/kg
I disse studier blev stoffet administreret ca. 24 timer efter kataraktkirurgi og behandlingen fortsatte i op til 14 dage. 
In these studies, study substance was administered approximately 24 hours after cataract surgery and continued for up to 14 days.
Efter dosering to gange daglig med bromfenac øjendråber var plasmakoncentrationerne ikke kvantificerbare. 
Following twice daily dosing with bromfenac eye drops plasma concentrations were not quantifiable.
Oversigt over sikkerhedsprofil 
Summary of the safety profile
Brug ikke lægemidlet efter den udløbsdato, der står på pakningen efter ”EXP”. 
Do not use this medicine after the expiry date which is stated on the bottle and outer carton after “EXP”.
Behandlingsvarighed 
Duration of treatment
Hos mennesker behandlet oralt er det uændrede lægemiddelstof hovedkomponenten i plasma. 
In orally treated humans unchanged parent compound is the major component in plasma.
Lægen kan dog ordinere dette lægemiddel til en gravid kvinde, hvis den forventede fordel for moderen opvejer den mulige risiko for barnet. 
The doctor may prescribe this medicine during pregnancy if expected benefit to mother outweigh possible risk to baby.
Patienter skal derfor tilrådes ikke at bruge kontaktlinser under behandlingen med Yellox. 
Therefore, patients should be advised not to wear contact lenses during treatment with Yellox.
Da den systemiske eksposition hos kvinder, der ikke er gravide er ubetydelig efter behandling med Yellox, kan risikoen under graviditet anses for at være lav. 
Since the systemic exposure in non-pregnant women is negligible after treatment with Yellox, the risk during pregnancy could be considered low.
- Hvis du haft astma, hudallergi eller intens betændelse i næsen ved brug af andre NSAID'er. 
- if you have experienced asthma, skin allergy or intense inflammation in your nose when using other NSAIDs.
Hvis det næsten er tid til den næste dosis, skal du springe den glemte dosis over. 
If it is almost time for the next dose, leave out the missed dose.
Nedenstående tabel beskriver bivirkninger i henhold til organklasser og frekvens. 
The table below describes adverse reactions by system organ class and frequency.
Koncentrationerne blev opretholdt i 12 timer i kammervæsken med målelige niveauer op til 24 timer i størstedelen af okulært væv, inklusive retina. 
Concentrations were maintained for 12 hours in aqueous humour with measurable levels up to 24 hours in major ocular tissues including the retina.
Yellox påvirker i mindre grad evnen til at føre motorkøretøj og betjene maskiner. 
Yellox has minor influence on the ability to drive and use machines.
Der blev ikke observeret nogen biologisk relevant melaninbinding in vitro. 
No biological relevant melanin binding was observed in vitro.
Advarsler og forsigtighedsregler 
Warning and precautions
Brug af kontaktlinser 
Use of contact lenses
I et stort velkontrolleret studie, der blev foretaget i Japan, viste Yellox sig at være lige så effektiv som pranoprofen okulær opløsning. 
In a large, well-controlled study that was conducted in Japan, Yellox was shown to be as effective as pranoprofen ophthalmic solution.
Efter oral administration af 14C-bromfenac til raske frivillige fandtes urinudskillelse at være den vigtigste rute for radioaktive udskillelser, idet den udgjorde ca. 82 %, mens fækal udskillelse repræsenterede ca. 13 % af dosen. 
After oral administration of 14C-bromfenac to healthy volunteers, urinary excretion was found to be the major route of radioactive excretions, accounting for approximately 82% while faecal excretion represented approximately 13% of the dose.
Kontakt lægen eller apotekspersonalet, før du bruger dette lægemiddel - Hvis du bruger topiske steroider (f.eks. kortison), da det kan medføre uønskede bivirkninger. 
Talk to your doctor or pharmacist before using this medicine - if you are using topical steroids (e.g. cortisone), as this may cause unwanted side effects.
Der er ikke rapporteret interaktioner med antibiotiske øjendråber brugt i forbindelse med kirurgi. 
No interactions with antibiotic eye drops used in conjunction with surgery have been reported.
- Hvis du har øjenproblemer (f.eks. tørre øjne, problemer med hornhinden). 
- if you have eye problems (e.g. dry eye syndrome, corneal problems).
Vand til injektioner Natriumhydroxid (til pH-justering) 
Water for injections Sodium hydroxide (for pH adjustment)
In vitro studier indikerer, at bromfenac hovedsageligt metaboliseres af CYP2C9, der er fraværende i både corpus ciliare i iris og i retina/choroidea, og at niveauet af dette enzym i cornea er mindre end 1 % sammenlignet med det tilsvarende leverniveau. 
In vitro studies indicate that bromfenac is mainly metabolised by CYP2C9, which is absent in both iris-ciliary body and retina/choroid and the level of this enzyme in the cornea is less than 1% compared to the corresponding hepatic level.
Skade på øjets overflade, rødme i øjet, astma. 
Damage of the eye surface, redness of the eye, asthma.
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal du spørge din læge til råds, før du bruger dette lægemiddel.. 
If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before you use Yellox.
Yellox indeholder bromfenac og tilhører en gruppe lægemidler, der kaldes non-steroide antiinflammatoriske lægemidler (NSAID'er). 
Yellox contains bromfenac and belongs to a group of medicines called non-steroidal antiinflammatory drugs (NSAIDs).
Flere konjugerede og ukonjugerede metabolitter er blevet identificeret med det cykliske amid som værende den vigtigste urinmetabolit. 
Several conjugated and unconjugated metabolites have been identified with the cyclic amide being the major urinary metabolite.
Fortsæt med øjendråberne i de første 2 uger efter operationen. 
Continue the drops through the first 2 weeks after your surgery.
0,9 mg/kg/dag hos rotter ved orale doser (900 gange den anbefalede okulærealmiske dosis) forårsagede imidlertid embryo-føtal letalitet, øget neonatal mortalitet og reduceret postnatal vækst. 
However, 0.9 mg/kg/day in rats at oral doses (900 times the recommended ophthalmic dose) caused embryofoetal lethality, increased neonatal mortality, and reduced postnatal growth.
Prækliniske data viser ingen speciel risiko for mennesker vurderet ud fra konventionelle studier af sikkerhedsfarmakologi, toksicitet efter gentagne doser, genotoksicitet og karcinogenicitet. 
Non-clinical data reveal no special hazard for humans based on conventional studies of safety, pharmacology, ‘repeated-dose' toxicity, genotoxicity and carcinogenic potential.
Der er ingen eller utilstrækkelige data for anvendelse af bromfenac til gravide kvinder. 
There are no adequate data from the use of bromfenac in pregnant women.
Bromfenac er et non-steroidt antiinflammatorisk middel (NSAID), som har antiinflammatorisk aktivitet, der anses for at skyldes dets evne til at blokere prostaglandinsyntese gennem primært at hæmme cyclooxygenase 2 (COX-2). 
Bromfenac is a non-steroidal anti-inflammatory drug (NSAID) that has anti-inflammatory activity which is thought to be due to its ability to block prostaglandin synthesis by inhibiting primarily cyclooxygenase 2 (COX-2).
SÆRLIG ADVARSEL OM, AT LÆGEMIDLET SKAL OPBEVARES UTILGÆNGELIGT FOR BØRN 
SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHTAND REACH OF CHILDREN
MÆRKNING, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE KARTON TIL ENKELT FLASKE 5 ML 
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON FOR SINGLE BOTTLE 5 ML
Farmakoterapeutisk klassifikation: Oftalmologiske midler, anti-inflammatoriske midler, non-steroider, ATC-kode: S01BC11 
Pharmacotherapeutic group: Ophtalmologicals, Antiinflammatory agents, non-steroids, ATC code: S01BC11.